



सत्यमेव जयते

वैद्य राजेश कोटेचा
Vaidya Rajesh Kotecha

सचिव

भारत सरकार

आयुर्वेद, योग व प्राकृतिक चिकित्सा
यूनानी, सिद्ध, सोवा रिग्पा एवं होम्योपैथी (आयुष) मंत्रालय
आयुष भवन, 'बी' ब्लॉक, जी.पी.ओ. कॉम्प्लेक्स,
आई एन.ए. नई दिल्ली-110023

SECRETARY

GOVERNMENT OF INDIA

MINISTRY OF AYURVEDA, YOGA & NATUROPATHY
UNANI, SIDDHA, SOWA-RIGPA AND HOMOEOPATHY (AYUSH)
AYUSH BHAWAN, B-BLOCK, GPO COMPLEX
INA, NEW DELHI-110023

Tel : 011-24651950, Fax : 011-24651937

E-mail : secy-ayush@nic.in

D.O. No. T-18020/1/2020-DCC-Part(1)

28th April, 2021

Dear Chief Secretary,

As you are aware, in the process of combating COVID 19 outbreak, the need for public use of Ayush based immuno-modulator products and medicines has been significantly emphasized and their demand has increased manifold. In this regard, I would like to inform that AYUSH 64, an Ayurvedic medicine was developed in compliance to all regulatory requirements and quality and pharmacopoeial standards by the Central Council for Research in Ayurvedic Sciences (CCRAS), an apex body for research in Ayurveda under the Ministry of AYUSH. This drug based on its ingredients having notable antiviral, immuno-modulator and antipyretic properties.

The Ministry of Ayush and CSIR collaboration has recently completed a robust multi-centre clinical trial to evaluate the efficacy and safety of AYUSH 64 in the management of mild to moderate COVID-19 patients and the results are highly encouraging and AYUSH 64 can be positioned as specific intervention for the management of asymptomatic, mild to moderate COVID-19 infection. Beside this the outcome of seven other clinical studies revealed that AYUSH 64 exhibit early clinical recovery in COVID-19 cases and help protect from progression of the disease to severe or critical stage.

This medicine is also recommended in National Clinical Management Protocol based on Ayurveda and Yoga for the management of asymptomatic and mild to moderate cases of COVID-19 which was vetted by National Task Force on COVID Management of ICMR (copy enclosed).

Therefore, utilization of AYUSH 64 in the asymptomatic, mild to moderate COVID-19 patients admitted in the hospital or isolated in their home is to be promoted under National Ayush Mission. State Licensing Authorities have been advised separately to facilitate Ayush Industries to increase production of AYUSH 64.

I, therefore, request you to do the needful for issuing necessary directions to the State Health Authorities to promote the use of AYUSH-64 as per National Clinical Management Protocol Based on Ayurveda and Yoga interventions.

With regards,

Encl. As above

To,

Chief Secretaries of all States/UTs

Yours sincerely,

RAJESH
KUMAR
KOTECHA

(Rajesh Kotecha)

Digitally signed by Rajesh Kumar Kotecha, DN: cn=Rajesh Kumar Kotecha, o=Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa-Rigpa and Homoeopathy (AYUSH), ou=Government of India, email=secy-ayush@nic.in, c=IN